BioVie Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
BIVI Nasdaq 2830 bioviepharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BioVie Inc.

New to The Street Show 773 Premieres Tonight on Bloomberg Television, Featuring Glint, Sagtec Global, BioVie and SafeSpace Global - Sep 26th, 2026 8:28 am
New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global - Sep 19th, 2026 9:45 am
Alliance Entertainment and BioVie Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV - Sep 18th, 2026 7:00 am
Join BioVie's Exclusive Live Investor Webinar: Inside the ADDRESS-LC Phase 2 Results - Sep 16th, 2026 7:00 am
BioVie Shares Fall 9.7% After Long COVID Trial Misses Statistical Significance in Full Population - Sep 15th, 2026 8:15 am
BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID - Sep 15th, 2026 5:30 am
BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid - Sep 14th, 2026 2:01 pm
BioVie’s lead therapy candidate shows improvement in key long COVID symptoms - Sep 10th, 2026 8:27 am
Dow closes sharply lower as oil surge fuels inflation fears - Sep 8th, 2026 8:10 am
BioVie advances Parkinson’s Phase 3 development program with FDA engagement - Sep 8th, 2026 7:52 am
BioVie Announces Update to Parkinson’s Phase 3 Development Program - Sep 8th, 2026 5:30 am
BioVie completes final patient visit in Phase 2 Long COVID trial - Aug 31st, 2026 7:05 am
BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID - Aug 31st, 2026 6:00 am
First Phosphate and BioVie Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV - Aug 14th, 2026 7:00 am
Parkinson's drug developers are betting big on inflammation - Aug 7th, 2026 11:13 am
Join Biovie's Exclusive Live Investor Webinar: Inside the SUNRISE-PD Topline Results - Aug 7th, 2026 7:00 am
BioVie stock sinks on Phase IIb Parkinson’s trial data - Aug 7th, 2026 5:05 am
BioVie reports positive Phase 2 results for Parkinson's candidate bezisterim - Aug 6th, 2026 7:03 am
BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s Disease - Aug 6th, 2026 5:30 am